ArticleApoptosis : an international journal on programmed cell death2026
Beyond the hype: the glycolysis-pyroptosis axis in intervertebral disc degeneration and the path to therapeutic translation.
Article in Apoptosis : an international journal on programmed cell death, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent study by Gao et al. (Apoptosis, 2025. https://doi.org/10.1007/s10495-025-02194-x ) proposes a compelling paradigm in which a positive feedback loop between glycolysis and nucleus pulposus cell pyroptosis acts as a central driver of intervertebral disc degeneration. Their work provides a crucial mechanistic link between dysregulated metabolism and inflammatory cell death, building upon long-standing observations of lactic acid accumulation and cellular demise in the degenerative disc. While this refined model represents a significant conceptual advance, our commentary identifies several layers of complexity that must be addressed for therapeutic translation. We argue that the proposed cycle operates within a highly specific pathophysiological context, with key concerns including the model's applicability across the disc's spatial heterogeneities, potential pathway redundancy upon therapeutic inhibition, and unresolved upstream instigators of the glycolytic shift. Future research must move beyond in vitro models to focus on spatially resolved mapping in human specimens, combinatorial therapeutic strategies, and elucidating the prime movers-mechanical, age-related, or senescent in origin-that initiate this vicious cycle.
Indexed as
Identifiers
41553567What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.